All News

The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.

Beneficiaries in ACOs receive significantly higher rates of primary and preventive services, signaling value-based care’s impact on quality and chronic disease management.

A spending bill advancing PBM reforms aims to delink Medicare Part D compensation from drug rebates and improve pricing transparency.

Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.

Maui Derm 2026 showcased groundbreaking advancements in dermatology, focusing on biologics, innovative treatments, and future technologies for skin health.

The Orphan Drug Act revolutionized rare disease treatment, yet rising costs and access issues challenge equitable health care solutions.

Obesity market overview for employers: data on GLP-1s for obesity, digital solutions, and benefit strategies to control costs and outcomes.

Aquestive Therapeutics receives a complete response letter for dibutepinephrine (Anaphylm), a sublingual epinephrine therapy.

Glaucoma is a leading cause of blindness in the US, making awareness of the condition vital to obtaining the best outcomes.

Addressing poor medication adherence should be a top priority in health plans to ensure short- and long-term benefits in health outcomes and financial stability.

Patients on commercial insurance were more likely to have at least 1 chronic condition, which can affect health care spending overall.

Communicating to patients that they need to come to their annual checkup is important for eye doctors to convey to help treat their patients, says Ariana Levin, MD.

These findings suggest the mental health burden in nonmelanoma skin cancer reflects broader social and clinical factors rather than disease-specific effects.

Tildrakizumab at 100-mg and 200-mg doses showed long-term effectiveness for managing psoriasis in challenging areas in a real-world study.

Vutrisiran significantly reduces mortality and cardiovascular events in older patients with ATTR-CM, enhancing quality of life and functional capacity.

Explore critical health equity issues as barriers to care access and health disparities that impact treatment for allergic rhinitis and childhood vaccinations.

Empathy, knowledge, and attitudes in care for patients with myasthenia gravis were improved when using a patient-centric immersive virtual reality intervention.

Discover how innovations in biology and engineering are transforming dermatology, featuring breakthroughs in laser therapies and precision medicine.

New research highlights the effectiveness of targeted therapies for metabolic dysfunction–associated steatohepatitis (MASH), guiding treatment decisions and trial designs.

Although there are no means of preventing glaucoma, there are means of preventing long-term vision loss.

Experts discuss the signs and symptoms, treatment methods, and the future of glaucoma as Glaucoma Awareness Month concludes.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Standard double reading did not perform as well as artificial intelligence for looking at catching cancer and reduced the rate of breast cancer diagnosis by 12%.

Vivian Shi, MD, discusses the evolving strategies for managing hidradenitis suppurativa, including biologics and combination therapies, at Maui Derm 2026.

New research suggests people with alopecia areata view hair regrowth efficacy as the most important factor when choosing a therapy, regardless of their disease severity.

The future of treating glaucoma relies on ophthalmologists and optometrists personalizing therapy to their patient, says Manjool Shah, MD.

Disparities in access to allo-HCT for AML persist, highlighting the need for targeted interventions to ensure equitable treatment for all patients.

This new study reveals venetoclax and rituximab effectively treat chronic lymphocytic leukemia, showing high response rates and prolonged progression-free survival.